Your Symptoms Aren’t Random. The Patterns May Be Easier to See Than You Think.

You've probably already done the thing where you try to explain your symptoms to a provider and watch their face go slightly blank. The fatigue that isn't tied to how much you slept. The joint pain that flares for no obvious reason. The day you feel clear and capable, followed by three days where getting dressed is the whole task list. At first blush, this may not sound like a pattern.

But more likely than not, there is a pattern. Maybe it's just one that most tracking tools, and most medical intake forms, aren't built to see.

Why your body looks "inconsistent" when it isn't

If you're hypermobile (hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD) are two common diagnoses) your connective tissue affects more than your joints. Research consistently shows measurable proprioceptive deficits in hypermobile joints, meaning your nervous system is doing extra background work all day just to stay oriented to where you are in space. Dysautonomia and POTS are common alongside hypermobility — reported in as many as three-quarters of hEDS/HSD cohorts — and produce symptoms that are characteristically posture-, heat-, food-, and exertion-dependent, which is exactly why they can look like they're coming out of nowhere.

Mast cell activation is also frequently reported in this population, with triggers that are genuinely varied — food, temperature, stress, chemical — and that shift over time. Perimenopause adds another layer: sex hormones influence mast cell behavior and are linked to autonomic changes during the menopausal transition. In other words, hormonal swings may be behind the seemingly unpredictable shifts in mast cell activity and vascular tone.

Tracking as data-gathering, not self-surveillance

This isn't about logging everything forever, and it isn't a wellness-culture habit where more discipline equals more virtue. The point of a symptom tracker is narrow and practical: you're building a baseline of your own system so you — and eventually your care team — can see what's actually connected, instead of relying on memory.

A useful daily log stays small: energy, pain, mood, sleep, and reactivity (skin, gut, breathing — whatever flares for you). That's it. Five data points, logged in whatever way takes you under a minute — a notes app, a symptom tracker, a smiley face on a paper calendar. The format matters far less than whether you'll actually do it on a bad day, not just a good one. Bad-day data is usually the data that matters most, and it's also the data people skip logging because logging feels like one more task on a day with no spare capacity. Lower the bar until skipping it isn't the easier option.

The second layer: mapping symptoms to your cycle

Once you have a couple of weeks of baseline data, the next layer is mapping it against where you are hormonally — follicular versus luteal, and if you're in perimenopause, noticing where the usual monthly pattern is starting to shift or disappear entirely. This is the layer that turns "I have good days and bad days" into a testable hypothesis: does reactivity spike in the week before your period? Does energy or orthostatic tolerance shift around the point where estrogen drops? Mast cells carry estrogen and progesterone receptors, and estrogen decline during the menopausal transition has been linked to autonomic changes, so a hormonal thread underneath your symptoms is biologically plausible. Whether it shows up that way for you is exactly what the tracking is for — this is a pattern to go looking for in your own data, not a guarantee about how your body will behave.

You don't need to track this with precision instruments — a notes app or paper log works fine for the symptom side. For symptom tracking with a menstrual cycle layer, Guava is the app I point people to. Pairing where you are in your cycle (or noting "unpredictable" if you're deep in perimenopause and it's stopped being predictable) next to your daily log is enough to start seeing whether there's a hormonal thread running underneath the noise.

Some people with MCAS feel like they're flaring the worst mid-cycle, when estrogen is highest. Others feel like pain is worst when hormones are low, near the beginning of menstruation. Each person is unique, making the act of tracking invaluable.

What tracking is — and isn't

A symptom log builds you a baseline and gives you and your provider something concrete to look at together. It is not, on its own, a diagnosis — hEDS, POTS, and MCAS each carry their own formal diagnostic criteria, and clinical guidance is still catching up to how often they overlap. Your tracking data can make conversations with your specialists faster and more productive, but it's not a substitute for a tailored medical workup.

What this actually gets you

After a few months, you may start to notice something you couldn't have caught in the moment — a trigger that's actually a pattern, a "bad week" that lines up with a hormonal phase every time, a recovery window that's longer than you'd been giving yourself credit for. That's the whole goal of befriending your body before you ask anything of it: you can't pace, nourish, or regulate a system you don't yet understand. The tracking isn't the destination. It's what makes every habit after it actually fit your body instead of a generic template that assumes a predictability you don't have.

If you're not sure yet whether hypermobility, MCAS, or dysautonomia are even part of your picture, try our Bendy Menopause Quiz, a two-minute check-in that helps you learn where to start.

References

  1. Afrin LB. Some Cases of Hypermobile Ehlers–Danlos Syndrome May Be Rooted in Mast Cell Activation Syndrome. American Journal of Medical Genetics Part C. 2021;187(4):466-472.

  2. Akaras E, Deniz G, Eymir M, Sönmez M. The Effects of Joint Hypermobility on Strength, Proprioception, and Functional Performance. Scientific Reports. 2025;15(1):40529.

  3. Russek LN, Stott P, Simmonds J. Recognizing and Effectively Managing Hypermobility-Related Conditions. Physical Therapy. 2019;99(9):1189-1200.

  4. Engelbert RH, Juul-Kristensen B, Pacey V, et al. The Evidence-Based Rationale for Physical Therapy Treatment of Children, Adolescents, and Adults Diagnosed With Joint Hypermobility Syndrome/Hypermobile Ehlers Danlos Syndrome. American Journal of Medical Genetics Part C. 2017;175(1):158-167.

  5. Dell'Aversana D, Provitera V, Trinchillo A, et al. Distinct Sensory and Autonomic Involvement in Hypermobile Ehlers-Danlos Syndrome Compared With Idiopathic Small Fiber Neuropathy: A Multimodal Study. Scientific Reports. 2026.

  6. Collins Hutchinson ML, Liang E, Fuster E, Blitshteyn S. Autonomic Symptom Burden, Comorbidities and Quality of Life in Women With Hypermobility Spectrum Disorders and Hypermobile Ehlers-Danlos Syndrome. Autonomic Neuroscience: Basic & Clinical. 2025;262:103356.

  7. Mathias CJ, Owens A, Iodice V, Hakim A. Dysautonomia in the Ehlers–Danlos Syndromes and Hypermobility Spectrum Disorders — With a Focus on the Postural Tachycardia Syndrome. American Journal of Medical Genetics Part C. 2021;187(4):510-519.

  8. Monaco A, Choi D, Uzun S, Maitland A, Riley B. Association of Mast-Cell-Related Conditions With Hypermobile Syndromes: A Review of the Literature. Immunologic Research. 2022;70(4):419-431.

  9. Brock I, Prendergast W, Maitland A. Mast Cell Activation Disease and Immunoglobulin Deficiency in Patients With Hypermobile Ehlers-Danlos Syndrome/Hypermobility Spectrum Disorder. American Journal of Medical Genetics Part C. 2021;187(4):473-481.

  10. Zierau O, Zenclussen AC, Jensen F. Role of Female Sex Hormones, Estradiol and Progesterone, in Mast Cell Behavior. Frontiers in Immunology. 2012;3:169.

  11. Redegeld FA, Yu Y, Kumari S, Charles N, Blank U. Non-IgE Mediated Mast Cell Activation. Immunological Reviews. 2018;282(1):87-113.

  12. Jensen F, Woudwyk M, Teles A, et al. Estradiol and Progesterone Regulate the Migration of Mast Cells From the Periphery to the Uterus and Induce Their Maturation and Degranulation. PloS One. 2010;5(12):e14409.

  13. Schwarz KG, Vicencio SC, Inestrosa NC, Villaseca P, Del Rio R. Autonomic Nervous System Dysfunction Throughout Menopausal Transition: A Potential Mechanism Underpinning Cardiovascular and Cognitive Alterations During Female Ageing. The Journal of Physiology. 2023.

  14. Lee EJ, Keller-Ross ML. Menopause and Its Effects on Autonomic Regulation of Blood Pressure: Insights and Perspectives. Autonomic Neuroscience: Basic & Clinical. 2025;260:103295.

  15. Aziz Q, Harris LA, Goodman BP, Simrén M, Shin A. AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review. Clinical Gastroenterology and Hepatology. 2025;23(8):1291-1302.

Next
Next

Is It Time to Rethink the Humble Oral Estrogen Pill?